Surveyor Capital, Cormorant Capital and Eventide Asset Management led a $110m funding round in VectivBio.

Investment firms Surveyor Capital, Cormorant Capital and Eventide Asset Management led a $110m funding round in VectivBio, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfer Initiative and Cowen Healthcare Investments. "We are excited by the addition of these accomplished crossover investors to our syndicate of top-tier investors. We look forward to continuing to advance apraglutide and to preparing our organization to bring a potential best-in-class therapy to people living with SBS," Luca Santarelli, VectivBio CEO.